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IMPORTANCE Sparse data and conflicting evidence exist on the prevalence of pulmonary
embolism (PE) in patients with syncope.
OBJECTIVE To estimate the prevalence of PE among patients presenting to the emergency
department (ED) for evaluation of syncope.
DESIGN, SETTING, AND PARTICIPANTS This retrospective, observational study analyzed
longitudinal administrative data from 5 databases in 4 different countries (Canada, Denmark,
Italy, and the United States). Data from all adult patients (aged18 years) who presented to
the EDwere screened to identify those with syncope codes at discharge. Data were collected
from January 1, 2000, through September 30, 2016.
MAIN OUTCOMES ANDMEASURES The prevalence of PE at ED and hospital discharge,
identified using codes from the International Classification of Diseases, was considered the
primary outcome. Two sensitivity analyses considering prevalence of PE at 90 days of
follow-up and prevalence of venous thromboembolismwere performed.
RESULTS A total of 1 671 944 unselected adults who presented to the ED for syncope were
included. The prevalence of PE, according to administrative data, ranged from0.06% (95%
CI, 0.05%-0.06%) to 0.55% (95% CI, 0.50%-0.61%) for all patients and from0.15% (95% CI,
0.14%-0.16%) to 2.10% (95% CI, 1.84%-2.39%) for hospitalized patients. The prevalence of
PE at 90 days of follow-up ranged from0.14% (95% CI, 0.13%-0.14%) to 0.83% (95% CI,
0.80%-0.86%) for all patients and from0.35% (95% CI, 0.34%-0.37%) to 2.63% (95% CI,
2.34%-2.95%) for hospitalized patients. Finally, the prevalence of venous thromboembolism
at 90 days ranged from0.30% (95% CI, 0.29%-0.31%) to 1.37% (95% CI, 1.33%-1.41%) for all
patients and from0.75% (95% CI, 0.73%-0.78%) to 3.86% (95% CI, 3.51%-4.24%) for
hospitalized patients.
CONCLUSIONS AND RELEVANCE Pulmonary embolismwas rarely identified in patients with
syncope. Although PE should be considered in every patient, not all patients should undergo
evaluation for PE.
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S yncope is a common symptom that occurs in 1 of 4people during their lifetime.1 Pulmonary embolism(PE) has long been recognized as an important and
serious cause of syncope. Data on its prevalence are scanty.
Several prospective studies enrolling patients with syncope
in the emergency department (ED) reported a prevalence of
less than 1.5%.2-11 These observational studies provided
good follow-up on patients but did not follow a structured
algorithm for the assessment of PE. A recent study (Pulmo-
nary Embolism in Syncope Italian Trial [PESIT])12 aiming at
evaluation of PE prevalence by using a standardized algo-
rithm in hospitalized patients after a first syncope episode
found a prevalence of PE in hospitalized patients as high as
17%. PESIT enrolled all patients hospitalized for a first epi-
sode of syncope and adopted a validated algorithm that was
based on pretest clinical probability and the result of the
D-dimer assay. Any patient with positive D-dimer findings
or high pretest PE probability, according to the Wells score,
underwent computed tomography or ventilation perfusion
lung scanning.12 Verma et al13 tried to replicate this study by
analyzing data from all patients admitted for syncope in 4
Canadian hospitals and found a much lower prevalence of
PE and venous thrombosis. Both studies considered only
hospitalized patients, which can make the data less general-
izable because the decision to admit a patient relies on mul-
tiple factors and the characteristics and admission rates are
very heterogeneous among different countries and health
care systems.6,14 Estimating PE prevalence in unselected
patients with syncope presenting to the ED would be more
informative because it would guide the decision as to
whether a systematic protocol for ruling out PE is
warranted.15-19
Large prospective studies from different health care sys-
tems could help solve this problem. However, these studies
would be expensive, time-consuming, and difficult to con-
duct. Therefore, administrative databases are an alternative
option todetermine theprevalenceof PE. The aimof thepres-
ent study was to determine the prevalence of PE in patients
with syncope using several international administrative da-
tabases.
Methods
Study Setting and Sources of Data
This retrospective, observational study used 5 longitudinal
administrative databases from Canada, Denmark, Italy, and
the United States. The databases analyzed included (1) all
inhabitants of the province of Alberta, Canada; (2) all inhabi-
tants of Denmark; (3) all inhabitants of the metropolitan area
of Milan, Italy; (4) data from the US Healthcare Cost and Utili-
zation Project; and (5) data from a large US national insurance
provider (Clinformatics Data Mart database; OptumInsight).
Data were collected from January 1, 2000, through Septem-
ber 30, 2016. The characteristics of each database are
described in the Box. The Alberta Ministry of Health, Agency
for Health Protection of the Province of Milan, and Agency
for Healthcare Research and Quality gave permission to use
deidentifed data for the present study; no ethics approval is
required for registry studies in Denmark. The University of
Alberta institutional review board, the Danish Data Protec-
tion Agency, and the Agency for Health Protection of the
Province of Milan approved the study. The institutional
review boards of Massachusetts General Hospital and Stan-
ford University determined that the project was exempt from
formal review.
Study Cohort
We applied uniform inclusion criteria to all data sets to iden-
tify all adult patients (aged ≥18 years) who presented to the
ED for evaluation of syncope. We used discharge codes in
any diagnosis field from the International Classification of
Diseases, Ninth Revision (ICD-9) (code 780.2) or the Interna-
tional Statistical Classification of Diseases and Related Health
Problems, Tenth Revision (ICD-10) (code R55), where appro-
priate, to identify adult patients who presented to the ED
with syncope.
Outcome
The prevalence of PE at ED and hospital discharge as defined
by ICD-9 and ICD-10 codeswas considered as theprimaryout-
come.ThepresenceofPEwasdeterminedat the firstEDevalu-
ation or immediate hospitalization using discharge codes 415
from the ICD-9 and I26 from the ICD-10.
Statistical Analysis
For each patient withmultiple ED visits for syncope, only the
first visit was considered the index evaluation for our analy-
sis. Data were reported as medians (interquartile range) and
counts (percentages) for descriptive purposes. The preva-
lences of the primary outcome were reported as proportions
with 95% CIs.
We performed 2 sensitivity analyses. First, we considered
all PE identified within 90 days of follow-up as being present
also at the index EDpresentation. This time framewas chosen
because90days is consideredanappropriate follow-uptoclini-
callyassess thepresenceorabsenceofPE.20-22 Second,wecon-
sideredas theworst-case scenario all identifiedvenous throm-
boembolismasPE.For thisanalysis,weconsidered ICD-9codes
415, 453.4, 453.5, 453.8, and 453.9 and ICD-10 codes I26, I801-
I803, I808, I809, I821-I823, I828, and I829.
Key Points
Question What is the estimated prevalence of pulmonary
embolism in patients who present to the emergency department
with syncope?
Findings In this study of 5 administrative databases that included
more than 1.5 million people from 4 different countries, pulmonary
embolismwas identified in less than 1% of patients with syncope.
Meaning Although pulmonary embolism should be considered at
first evaluation in every patient with syncope, not all patients
warrant a diagnostic algorithm to exclude it, and the algorithm
may increase false-positive results and overtreatment, resulting in
more adverse events.
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All analyses were performed for patients who presented
in the ED with syncope and in the subgroup of patients hos-
pitalized for syncope. The analyses were conducted for each
cohort separately using SAS statistical software (version 9.4;
SAS Institute, Inc).
Results
The combined database included 1 671 944 adult patients
presenting to the ED for syncope from 4 different countries.
Descriptive characteristics of the databases are reported
in Table 1 . The rate of PE diagnosis ranged from
0.06% (95% CI, 0.05%-0.06%) to 0.55% (95% CI, 0.50%-
0.61%) of all patients who presented in the ED for syncope,
according to administrative data. When considering the
subgroup of hospitalized patients, PE diagnosis ranged from
0.15% (95% CI, 0.14%-0.16%) to 2.10% (95% CI, 1.84%-
2.39%).
Sensitivity Analyses
Diagnoses of PEwithin 90days of follow-up, according to ad-
ministrative data, ranged from 0.14% (95% CI, 0.13%-0.14%)
to 0.83% (95% CI, 0.80%-0.86%) for all patients and from
0.35% (95% CI, 0.34%-0.37%) to 2.63% (95% CI, 2.34%-
2.95%) for hospitalized patients. Finally, the identification of
venous thromboembolismwithin90days ranged from0.30%
(95% CI, 0.29%-0.31%) to 1.37% (95% CI, 1.33%-1.41%) for all
patients and from0.75%(95%CI,0.73%-0.78%) to3.86%(95%
CI, 3.51%-4.24%) in the subgroupofhospitalizedpatients.De-
tails of the results of eachdatabase are reported inTable 2 and
Table 3.
Box. Characteristics of the Analyzed Databases
Canada
Data from all the inhabitants of Alberta, the fourth largest province
in western Canada with a population of approximately 4.2 million,
were retrieved. The following databases, maintained by the Alberta
Ministry of Health, were linked: (1) the Ambulatory Care
Classification System Database, which records all visits to
hospital-based physician offices or emergency departments (EDs)
and includes as many as 10 diagnosis fields; (2) the inpatient
Discharge Abstract Database that records information for all acute
care hospitalizations (dates, principal diagnosis, and24 other
diagnoses, procedures, length of stay, and discharge status); (3) the
Alberta Health Care Insurance Plan, the population registry that
records basic demographic and geographic information for all
residents; and (4) the Alberta Vital Statistics database, which
records all deaths in the province. The codification system is based
on International Statistical Classification of Diseases and Related
Health Problems, Tenth Revision (ICD-10). Each patient has a unique
personal identifier that allows linkage of patient information across
the databases. The period considered was April 1, 2006, through
December 31, 2013. As many as 10 diagnosis fields were permitted in
the ED, whereas up to 25 were permitted in the hospitalization
database.
Denmark
Data from all inhabitants of Denmark, with a population of
approximately 5.5 million, were retrieved. All ICD discharge codes
from the ED and hospital are maintained by the National Health
System using ICD-10 codes. Each patient has a unique personal
identifier, and admission rate has been calculated as patients
discharged from the ED and admitted in hospital in the same day.
The period considered for the analysis was January 1, 2000, through
September 30, 2012.
Italy
Data from all the inhabitants of the metropolitan area of Milan, with
a population of approximately 3.2 million, were retrieved. The
following databases, maintained by the Health Information System
of the Health Protection Agency, were linked: (1) ED visits (coded in
International Classification of Diseases, Ninth Revision, Clinical
Modification [ICD-9-CM]); (2) hospitalizations (coded in ICD-9-CM);
(3) and the Nominative Causes of Death Registry (coded in ICD-10).
These sources covered all direct medical costs attributable to the
Italian National Health Service and all deaths that occurred at the
population level. Each patient has a unique personal identifier
allowing linkage of patient information across the databases. The
period considered was January 1, 2014, through September 30,
2016. As many as 2 diagnosis fields were permitted in the ED,
whereas up to 5 were permitted in the hospitalization database.
USHealthcare Cost andUtilization Project
The population-based data from the Healthcare Cost and Utilization
Project (HCUP) State Emergency Department Databases and State
Inpatient Databases of 5 US states—California, Florida, Nebraska,
New York, and Utah—were used. The HCUP is a family of health care
databases developed through a federal-state-industry partnership
and sponsored by the Agency for Healthcare Research and Quality.
The State Emergency Department Databases includes all
treat-and-release and transfer ED visits from short-term, acute-care,
nonfederal hospitals in participating states. The State Inpatient
Databases includes all inpatient discharges from short-term,
acute-care, nonfederal, general, and other specialty hospitals,
including those admitted from the ED. Taken together, we identified
all ED visits regardless of disposition and all hospitalizations
regardless of the source. The period considered was January 1, 2007,
through December 31, 2011. The ICD-9-CM code has been used. The
number of residents, derived from the US Census in 2010, was
approximately 80million. The number of diagnosis fields varied
from 9 to 31 according to the analyzed states.
USNational Insurance Provider Database
A large national insurance provider maintained a deidentified
database (ClinformaticsTMData Mart Database; OptumInsight). The
entire database involves 58million uniquemembers representing
50 states. The database contains 12 to 14million members each year,
of whom 2.5 to 3.5 million are Medicare beneficiaries. Of these
members, 78% are continually insured for 6months, andmembers
compare favorably to most US population benchmarks, although
African American persons and those of lower socioeconomic status
are underrepresented in the private insurer market and also in this
database. ED visits for syncope were retrieved from claims data
using the ICD-9 and ICD-10 codes. Each patient has a unique personal
identifier allowing linkage of patient information across the
databases. The period considered was January 1, 2004, through
December 31, 2015. As many as 5 diagnosis fields were permitted.
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Discussion
Our results, based on administrative data, show that PE was
identified in less than 1% of all patients with syncope and in
less than 3% of hospitalized patients with syncope. Pulmo-
nary embolism has always been considered an uncommon
cause of syncope. Several prospective cohort studies enroll-
ing consecutive patientswith syncope in the ED4,5,9,14,19 have
reported a PE prevalence of less than 1% at 7 to 30 days of fol-
low-up. Retrospective data from the United States23 con-
firmed such results. The recently published PESIT12 was spe-
cifically aimed at evaluating PE prevalence in syncope by
applying a standardized diagnostic protocol for all the pa-
tients admitted to the hospital for their first episode of syn-
cope. According to the investigators, the prevalence of PE can
be ashigh as 17% inpatients hospitalized for first syncope and
as high as 3.7% in all patients presenting to the ED with syn-
cope. Verma et al13 retrospectively applied the PESIT inclu-
sion criteria inCanada and reported aprevalence of PE and/or
deep venous thrombosis of 1.4%. These conflicting results
leave physicians uncertain as to whether they should follow
a structured diagnostic pathway to rule out PE in all patients
with syncope, with the risks being overdiagnosis and
overtreatment.15-19,23 The results of the present study, an in-
ternational collaborationof 5 groups, considereddifferent ad-
ministrative databases from 4 different countries, involved
more than 1.5 million patients, and confirmed that PE preva-
lence in patients with syncope is low.13,22
Because the admission rates are known tobe veryhetero-
geneous, as confirmedbythepresent study,wedecided tocon-
sider hospitalized and nonhospitalized patients separately to
increase thegeneralizabilityof the results.6-8,24BecausePESIT
used a structured algorithm to assess for the presence of PE,
one could hypothesize that previous studies, as well as
clinical practice, might have underestimated PE prevalence.
Even in the present study, some PE diagnoses could have
been missed because they were not suspected, and there-
fore no information relevant to PE was reported in the
administrative data. However, to identify all possible cases
of unrecognized PE, we performed a sensitivity analysis in
which all events diagnosed within 90 days as syncope-
related PE were considered.20-22,25 Even in this case, PE was
identified in less than 1% of patients, suggesting that, even
if some PE had been missed at first evaluation, most were
not clinically relevant.
Our results are consistent with those of most single
studies recruiting patients with syncope in the ED and
assessing them within different time frames,2-5,13 which
reported a PE prevalence of less than 1.5%. Moreover, meta-
analyses of these studies24,26,27 reported the same preva-
lence. Although we used the same inclusion criteria, we
observed some variation in PE identification among the
countries and databases we used. This variation is not sur-
prising given the difference in health care systems, the
population enrolled, physician incentives to investigate,
and variations of insurance coverage and type among all the
data sets (Box). This high variability was expected as a con-Ta
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sequence of our decision to include heterogeneous contexts.
However, despite this variation, the rate of identification of
PE is low and significantly lower than that reported in PESIT
regardless of the data set considered. Different hypotheses
could be proposed to explain the higher PE prevalence found
in the PESIT study. First, using a structured algorithm to
assess PE might have led to an increase in the use of com-
puted tomography and scintigraphy. This methodmight have
led to an increase in the identification of subsegmental PE,
for which clinical relevance is debated, and false-positive
results.16 Finally, the design of the PESIT study, which
enrolled only hospitalized patients, might have led to the
inclusion of patients at higher PE risk.
Our study has relevant clinical implications; our findings
discourage the adoption of a routine protocol for excluding PE
in all patients presenting to the ED with syncope. The unnec-
essary exposure to radiation and the risk of contrast allergy is
significant. Furthermore, the false-positive rate of tests, such
astheD-dimerassayandcomputedtomographicpulmonaryan-
giograms, is high, leading tomore tests and overdiagnosis and
includingrisksofunnecessaryanticoagulation.13,16-18,23,28,29Be-
yond the risks, these tests are expensive and time consuming.
Wedonot advocate that physicians should disregard the pres-
enceofPE inpatientswithsyncope.Thedecision topursue fur-
ther investigations should be determined by the risk of the pa-
tient for that outcome and the incidence of the outcome in the
populationconsidered.30Our studyshows thatPEdiagnosis in
patientswith syncope is too low to justify a standardizeddiag-
nostic algorithm for PE in every patient.
Limitations
Themain limitationofour study is theuseofadministrativeda-
tabases to identifypatientswith syncopeandPE.Although the
sensitivity and specificity of ICD-9 and ICD-10 codes for PE are
higher than 90%, the validation of the codes for syncope re-
sultedinahighspecificityandpositivepredictivevaluebutmod-
erate sensitivity.31,32 Therefore, some patients were likely
missed.However, because fewpatientswith syncope receive a
PEdiagnosis intheED,ourprevalenceshouldnothavebeensub-
stantiallyaffected.6-8Moreover,mostofthemissedpatientswith
syncope were those with an established diagnosis reached in
the ED inwhom syncope has been considered only the conse-
quence of the primary diagnosis. For this reason, other dis-
charge codes instead of the ones for syncope could have been
used. Use of these codes could lead to the overrepresentation
of patientswith indeterminate syncope. Indeed, in the clinical
setting, the main interest of clinicians is to exclude PE in pa-
tientswith indeterminate syncope rather than in patientswho
already have an etiologic diagnosis of syncope.33
We have not assessed the influence of some patient char-
acteristics, such as sex, age, and comorbidities, on the diag-
nosis of venous thromboembolism. In addition, we have not
analyzed the trend of venous thromboembolism identifica-
tion through time. However, we decided to focus the present
study on the prevalence of PE in patients with syncope. Fi-
nally, some patients could have been included in both US da-
tabases. Because data are deidentified, we cannot adjust for
this overlap. Considering the small degree of overlap, we de-
cided to keep both databases and to analyze them separately.
Table 3. PE Identification in the Subgroup of Patients Hospitalized for Syncope After the First ED Evaluation, According to Administrative Databases
Country
PE at First Evaluationa PE Within 90 Days VTE Within 90 Days
Prevalence, %
(95% CI)
No./No. Undergoing
Evaluation
Prevalence, %
(95% CI)
No./No. Undergoing
Evaluation
Prevalence, %
(95% CI)
No./No. Undergoing
Evaluation
Canada 2.10 (1.84-2.39) 233/11 087 2.63 (2.34-2.95) 292/11 087 3.86 (3.51-4.24) 428/11 087
Denmark 0.58 (0.48-0.68) 139/24 144 0.75 (0.64-0.87) 181/24 144 0.99 (0.87-1.12) 239/24 144
Italy 0.84 (0.62-1.11) 47/5598 1.05 (0.80-1.36) 59/5598 1.23 (0.96-1.56) 69/5598
United States (HCUP) 0.15 (0.14-0.16) 563/362 793 0.35 (0.34-0.37) 1286/362 793 0.75 (0.73-0.78) 2731/362 793
United States
(national insurance
provider)
1.46 (1.40-1.53) 1739/118 842 1.89 (1.82-1.97) 2251/118 842 2.99 (2.90-3.09) 3559/118 842
Abbreviations: ED, emergency department; HCUP, Healthcare Cost and
Utilization Project; PE, pulmonary embolism; VTE, venous thromboembolism.
a Considered to occur during the first presentation in the ED for syncope and/or
immediate hospitalization.
Table 2. PE Identification in All Patients Presenting to the ED for Syncope, According to Administrative Databases
Country
PE At First Evaluationa PE Within 90 d VTE Within 90 d
Prevalence, %
(95% CI)
No./No. Undergoing
Evaluation
Prevalence, %
(95% CI)
No./No. Underoging
Evaluation
Prevalence, %
(95% CI)
No./No. Undergoing
Evaluation
Canada 0.55 (0.50-0.61) 370/67 243 0.80 (0.73-0.87) 538/67 243 1.24 (1.15-1.32) 831/67 243
Denmark 0.25 (0.21-0.29) 142/57 500 0.37 (0.32-0.42) 212/57 500 0.55 (0.49-0.61) 315/57 500
Italy 0.19 (0.14-0.24) 55/29 543 0.28 (0.23-0.35) 84/29 543 0.34 (0.28-0.41) 100/29 543
United States (HCUP) 0.06 (0.05-0.06) 684/1 190 621 0.14 (0.13-0.14) 1621/1 190 621 0.30 (0.29-0.31) 3574/1 190 621
United States
(national insurance
provider)
0.55 (0.52-0.58) 1798/327 037 0.83 (0.80-0.86) 2706/327 037 1.37 (1.33-1.41) 4467/327 037
Abbreviations: ED, emergency department; HCUP, Healthcare Cost and
Utilization Project; PE, pulmonary embolism; VTE, venous thromboembolism.
a Considered to occur during the first presentation in the ED for syncope and/or
immediate hospitalization.
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Conclusions
The results of thepresent study confirm that PE is rarely iden-
tified in patients presenting to the ED with syncope. Al-
though PE should be considered as a differential diagnosis
in every patient, not all patients warrant an evaluation for it.
Otherwise, evaluation could lead to false-positive results and
overtreatment, thereby increasing adverse events and health
care costs.
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